ID   AK1C4_HUMAN             Reviewed;         323 AA.
AC   P17516; Q5T6A3; Q8WW84; Q9NS54;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 3.
DT   07-APR-2021, entry version 212.
DE   RecName: Full=Aldo-keto reductase family 1 member C4;
DE            EC=1.1.1.- {ECO:0000269|PubMed:10634139, ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:11158055, ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:19218247, ECO:0000269|PubMed:2427522, ECO:0000269|PubMed:7650035, ECO:0000269|PubMed:8172617};
DE            EC=1.1.1.209 {ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:7650035};
DE            EC=1.1.1.210 {ECO:0000269|PubMed:14672942};
DE            EC=1.1.1.51 {ECO:0000269|PubMed:10998348};
DE            EC=1.1.1.53 {ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:14672942};
DE            EC=1.1.1.62 {ECO:0000269|PubMed:10998348};
DE   AltName: Full=3-alpha-hydroxysteroid dehydrogenase type I {ECO:0000303|PubMed:11158055, ECO:0000303|PubMed:7650035};
DE            Short=3-alpha-HSD1 {ECO:0000303|PubMed:11158055};
DE            EC=1.1.1.357 {ECO:0000269|PubMed:10634139, ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:11158055, ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:19218247, ECO:0000269|PubMed:7650035, ECO:0000269|PubMed:8172617};
DE   AltName: Full=3alpha-hydroxysteroid 3-dehydrogenase;
DE   AltName: Full=Chlordecone reductase {ECO:0000303|PubMed:2427522};
DE            Short=CDR;
DE            EC=1.1.1.225 {ECO:0000269|PubMed:2427522};
DE   AltName: Full=Dihydrodiol dehydrogenase 4;
DE            Short=DD-4;
DE            Short=DD4;
DE   AltName: Full=HAKRA;
GN   Name=AKR1C4; Synonyms=CHDR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-250.
RC   TISSUE=Liver;
RX   PubMed=8274401; DOI=10.1016/0960-0760(93)90308-j;
RA   Qin K.-N., New M.I., Cheng K.-C.;
RT   "Molecular cloning of multiple cDNAs encoding human enzymes structurally
RT   related to 3 alpha-hydroxysteroid dehydrogenase.";
RL   J. Steroid Biochem. Mol. Biol. 46:673-679(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, VARIANT ARG-250,
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=7650035; DOI=10.1074/jbc.270.34.20162;
RA   Khanna M., Qin K.-N., Wang R.W., Cheng K.-C.;
RT   "Substrate specificity, gene structure, and tissue-specific distribution of
RT   multiple human 3 alpha-hydroxysteroid dehydrogenases.";
RL   J. Biol. Chem. 270:20162-20168(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-250.
RX   PubMed=7626489; DOI=10.1016/0960-0760(95)00019-v;
RA   Khanna M., Qin K.-N., Cheng K.-C.;
RT   "Distribution of 3 alpha-hydroxysteroid dehydrogenase in rat brain and
RT   molecular cloning of multiple cDNAs encoding structurally related proteins
RT   in humans.";
RL   J. Steroid Biochem. Mol. Biol. 53:41-46(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANTS CYS-145; ARG-250 AND VAL-311,
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RC   TISSUE=Liver;
RX   PubMed=10634139;
RA   Kume T., Iwasa H., Shiraishi H., Yokoi T., Nagashima K., Otsuka M.,
RA   Terada T., Takagi T., Hara A., Kamataki T.;
RT   "Characterization of a novel variant (S145C/L311V) of 3alpha-
RT   hydroxysteroid/dihydrodiol dehydrogenase in human liver.";
RL   Pharmacogenetics 9:763-771(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT ARG-250.
RC   TISSUE=Liver;
RX   PubMed=10672042; DOI=10.1046/j.1365-2443.2000.00310.x;
RA   Nishizawa M., Nakajima T., Yasuda K., Kanzaki H., Sasaguri Y., Watanabe K.,
RA   Ito S.;
RT   "Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with
RT   three aldo-keto reductase genes.";
RL   Genes Cells 5:111-125(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, TISSUE
RP   SPECIFICITY, VARIANT ARG-250, AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Liver;
RX   PubMed=11158055; DOI=10.1210/jcem.86.2.7216;
RA   Dufort I., Labrie F., Luu-The V.;
RT   "Human types 1 and 3 3 alpha-hydroxysteroid dehydrogenases: differential
RT   lability and tissue distribution.";
RL   J. Clin. Endocrinol. Metab. 86:841-846(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS TYR-170 AND ARG-250.
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-323, AND VARIANT ARG-250.
RC   TISSUE=Liver;
RX   PubMed=2187532; DOI=10.1021/bi00456a034;
RA   Winters C.J., Molowa D.T., Guzelian P.S.;
RT   "Isolation and characterization of cloned cDNAs encoding human liver
RT   chlordecone reductase.";
RL   Biochemistry 29:1080-1087(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3-323, PROTEIN SEQUENCE OF 5-29; 76-131;
RP   184-201 AND 271-294, AND VARIANT ARG-250.
RC   TISSUE=Liver;
RX   PubMed=8172617; DOI=10.1042/bj2990545;
RA   Deyashiki Y., Ogasawara A., Nakayama T., Nakanishi M., Miyabe Y., Sato K.,
RA   Hara A.;
RT   "Molecular cloning of two human liver 3 alpha-hydroxysteroid/dihydrodiol
RT   dehydrogenase isoenzymes that are identical with chlordecone reductase and
RT   bile-acid binder.";
RL   Biochem. J. 299:545-552(1994).
RN   [11]
RP   PROTEIN SEQUENCE OF 40-54; 105-121; 162-175; 184-196; 277-291 AND 307-321,
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=1530633; DOI=10.1016/0006-291x(92)91260-w;
RA   Binstock J.M., Iyer R.B., Hamby C.V., Fried V.A., Schwartz I.S.,
RA   Weinstein B.I., Southren A.L.;
RT   "Human hepatic 3 alpha-hydroxysteroid dehydrogenase: possible identity with
RT   human hepatic chlordecone reductase.";
RL   Biochem. Biophys. Res. Commun. 187:760-766(1992).
RN   [12]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=2427522;
RA   Molowa D.T., Shayne A.G., Guzelian P.S.;
RT   "Purification and characterization of chlordecone reductase from human
RT   liver.";
RL   J. Biol. Chem. 261:12624-12627(1986).
RN   [13]
RP   CATALYTIC ACTIVITY, FUNCTION, TISSUE SPECIFICITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND SUBSTRATE SPECIFICITY.
RX   PubMed=10998348; DOI=10.1042/0264-6021:3510067;
RA   Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K., Ma H.,
RA   Moore M., Palackal N., Ratnam K.;
RT   "Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the
RT   aldo-keto reductase superfamily: functional plasticity and tissue
RT   distribution reveals roles in the inactivation and formation of male and
RT   female sex hormones.";
RL   Biochem. J. 351:67-77(2000).
RN   [14]
RP   CATALYTIC ACTIVITY, FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=14672942; DOI=10.1074/jbc.m313308200;
RA   Steckelbroeck S., Jin Y., Gopishetty S., Oyesanmi B., Penning T.M.;
RT   "Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto
RT   reductase superfamily display significant 3beta-hydroxysteroid
RT   dehydrogenase activity: implications for steroid hormone metabolism and
RT   action.";
RL   J. Biol. Chem. 279:10784-10795(2004).
RN   [15]
RP   CATALYTIC ACTIVITY, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=19218247; DOI=10.1074/jbc.m809465200;
RA   Jin Y., Duan L., Lee S.H., Kloosterboer H.J., Blair I.A., Penning T.M.;
RT   "Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase
RT   superfamily catalyze reduction of conjugated steroids: implications for
RT   phase I and phase II steroid hormone metabolism.";
RL   J. Biol. Chem. 284:10013-10022(2009).
RN   [16]
RP   INVOLVEMENT IN SRXY8.
RX   PubMed=21802064; DOI=10.1016/j.ajhg.2011.06.009;
RA   Fluck C.E., Meyer-Boni M., Pandey A.V., Kempna P., Miller W.L.,
RA   Schoenle E.J., Biason-Lauber A.;
RT   "Why boys will be boys: two pathways of fetal testicular androgen
RT   biosynthesis are needed for male sexual differentiation.";
RL   Am. J. Hum. Genet. 89:201-218(2011).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH NADP.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human 3-alpha hydroxysteroid/dihydrodiol
RT   dehydrogenase (AKR1C4) complexed with NADP+.";
RL   Submitted (FEB-2006) to the PDB data bank.
CC   -!- FUNCTION: Cytosolic aldo-keto reductase that catalyzes the NADH and
CC       NADPH-dependent reduction of ketosteroids to hydroxysteroids. Liver
CC       specific enzyme that acts as NAD(P)(H)-dependent 3-, 17- and 20-
CC       ketosteroid reductase on the steroid nucleus and side chain
CC       (PubMed:14672942, PubMed:10998348, PubMed:7650035, PubMed:1530633,
CC       PubMed:11158055, PubMed:10634139, PubMed:19218247). Displays the
CC       ability to catalyze both oxidation and reduction in vitro, but most
CC       probably acts as a reductase in vivo since the oxidase activity
CC       measured in vitro is inhibited by physiological concentration of NADPH
CC       (PubMed:14672942). Acts preferentially as a 3-alpha-hydroxysteroid
CC       dehydrogenase (HSD) with a subsidiary 3-beta-HSD activity
CC       (PubMed:14672942). Catalyzes efficiently the transformation of the
CC       potent androgen 5-alpha-dihydrotestosterone (5alpha-DHT or 17beta-
CC       hydroxy-5alpha-androstan-3-one) into the less active form, 5-alpha-
CC       androstan-3-alpha,17-beta-diol (3-alpha-diol) (PubMed:11158055,
CC       PubMed:10998348, PubMed:14672942). Catalyzes the reduction of estrone
CC       into 17beta-estradiol but with low efficiency (PubMed:14672942).
CC       Metabolizes a broad spectrum of natural and synthetic therapeutic
CC       steroid and plays an important role in metabolism of androgens,
CC       estrogens, progestereone and conjugated steroids (PubMed:10998348,
CC       PubMed:14672942, PubMed:19218247). Catalyzes the biotransformation of
CC       the pesticide chlordecone (kepone) to its corresponding alcohol leading
CC       to increased biliary excretion of the pesticide and concomitant
CC       reduction of its neurotoxicity since bile is the major excretory route
CC       (PubMed:2427522). {ECO:0000269|PubMed:10634139,
CC       ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:11158055,
CC       ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:1530633,
CC       ECO:0000269|PubMed:19218247, ECO:0000269|PubMed:2427522,
CC       ECO:0000269|PubMed:7650035}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3alpha-hydroxysteroid + NADP(+) = a 3-oxosteroid + H(+) +
CC         NADPH; Xref=Rhea:RHEA:34783, ChEBI:CHEBI:15378, ChEBI:CHEBI:36835,
CC         ChEBI:CHEBI:47788, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         EC=1.1.1.357; Evidence={ECO:0000269|PubMed:10634139,
CC         ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:11158055,
CC         ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:19218247,
CC         ECO:0000269|PubMed:7650035, ECO:0000269|PubMed:8172617};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3alpha-hydroxysteroid + NAD(+) = a 3-oxosteroid + H(+) +
CC         NADH; Xref=Rhea:RHEA:34779, ChEBI:CHEBI:15378, ChEBI:CHEBI:36835,
CC         ChEBI:CHEBI:47788, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945;
CC         EC=1.1.1.357; Evidence={ECO:0000269|PubMed:10634139,
CC         ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:11158055,
CC         ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:19218247,
CC         ECO:0000269|PubMed:7650035, ECO:0000269|PubMed:8172617};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3alpha,17beta-diol + NADP(+) = 17beta-
CC         hydroxy-5alpha-androstan-3-one + H(+) + NADPH; Xref=Rhea:RHEA:42116,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16330, ChEBI:CHEBI:36713,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:11158055,
CC         ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:19218247};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42118;
CC         Evidence={ECO:0000305|PubMed:10998348, ECO:0000305|PubMed:14672942,
CC         ECO:0000305|PubMed:19218247};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3beta,17beta-diol + NADP(+) = 17beta-
CC         hydroxy-5alpha-androstan-3-one + H(+) + NADPH; Xref=Rhea:RHEA:16297,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16330, ChEBI:CHEBI:18329,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.210;
CC         Evidence={ECO:0000269|PubMed:14672942};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:16299;
CC         Evidence={ECO:0000305|PubMed:14672942};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3alpha,17beta-diol + NAD(+) = 17beta-
CC         hydroxy-5alpha-androstan-3-one + H(+) + NADH; Xref=Rhea:RHEA:42004,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16330, ChEBI:CHEBI:36713,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.53;
CC         Evidence={ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:14672942};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42005;
CC         Evidence={ECO:0000305|PubMed:14672942};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42006;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=17beta-estradiol + NADP(+) = estrone + H(+) + NADPH;
CC         Xref=Rhea:RHEA:24616, ChEBI:CHEBI:15378, ChEBI:CHEBI:16469,
CC         ChEBI:CHEBI:17263, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.62;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:24617;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:24618;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=17beta-estradiol + NAD(+) = estrone + H(+) + NADH;
CC         Xref=Rhea:RHEA:24612, ChEBI:CHEBI:15378, ChEBI:CHEBI:16469,
CC         ChEBI:CHEBI:17263, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.62;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:24613;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:24614;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(20S)-hydroxypregn-4-en-3-one + NADP(+) = H(+) + NADPH +
CC         progesterone; Xref=Rhea:RHEA:42112, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17026, ChEBI:CHEBI:28453, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349; Evidence={ECO:0000269|PubMed:10998348,
CC         ECO:0000269|PubMed:11158055};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42113;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42114;
CC         Evidence={ECO:0000269|PubMed:11158055, ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(20S)-hydroxypregn-4-en-3-one + NAD(+) = H(+) + NADH +
CC         progesterone; Xref=Rhea:RHEA:42108, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17026, ChEBI:CHEBI:28453, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:57945; Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42109;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42110;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3alpha-hydroxy-5alpha-androstan-17-one + NADP(+) = 5alpha-
CC         androstan-3,17-dione + H(+) + NADPH; Xref=Rhea:RHEA:20377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:15994, ChEBI:CHEBI:16032,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.209;
CC         Evidence={ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:7650035};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20378;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=NADP(+) + testosterone = androst-4-ene-3,17-dione + H(+) +
CC         NADPH; Xref=Rhea:RHEA:14981, ChEBI:CHEBI:15378, ChEBI:CHEBI:16422,
CC         ChEBI:CHEBI:17347, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.51;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:14982;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=NAD(+) + testosterone = androst-4-ene-3,17-dione + H(+) +
CC         NADH; Xref=Rhea:RHEA:14929, ChEBI:CHEBI:15378, ChEBI:CHEBI:16422,
CC         ChEBI:CHEBI:17347, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.51;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:14930;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3alpha-hydroxy-5alpha-androstane 17-O-(beta-D-glucuronate) +
CC         NADP(+) = 5alpha-dihydrotestosterone 17-O-(beta-D-glucuronate) + H(+)
CC         + NADPH; Xref=Rhea:RHEA:53112, ChEBI:CHEBI:15378, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:133519, ChEBI:CHEBI:136914;
CC         Evidence={ECO:0000269|PubMed:19218247};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:53114;
CC         Evidence={ECO:0000305|PubMed:19218247};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(3beta,5alpha,17beta)-3-hydroxy-androstan-17-yl sulfate +
CC         NADP(+) = 5alpha-dihydrotestosterone sulfate + H(+) + NADPH;
CC         Xref=Rhea:RHEA:53136, ChEBI:CHEBI:15378, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:133105, ChEBI:CHEBI:136982;
CC         Evidence={ECO:0000269|PubMed:19218247};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:53138;
CC         Evidence={ECO:0000305|PubMed:19218247};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3alpha,17beta-diol + NAD(+) = 3alpha-
CC         hydroxy-5alpha-androstan-17-one + H(+) + NADH; Xref=Rhea:RHEA:42124,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16032, ChEBI:CHEBI:36713,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945;
CC         Evidence={ECO:0000269|PubMed:14672942};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42125;
CC         Evidence={ECO:0000305|PubMed:14672942};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=chlordecone alcohol + NADP(+) = chlordecone + H(+) + NADPH;
CC         Xref=Rhea:RHEA:14401, ChEBI:CHEBI:15378, ChEBI:CHEBI:16548,
CC         ChEBI:CHEBI:17184, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         EC=1.1.1.225; Evidence={ECO:0000269|PubMed:2187532};
CC   -!- ACTIVITY REGULATION: Inhibited by nonsteroidal the anti-inflammatory
CC       drugs (NSAID) flufenamic (PubMed:14672942). The oxidation reaction is
CC       inhibited by low micromolar concentrations of NADPH (PubMed:14672942).
CC       {ECO:0000269|PubMed:14672942}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=10.5 uM for 5alpha-androstane-3alpha,17beta-diol
CC         {ECO:0000269|PubMed:10998348};
CC         KM=8.3 uM for 17beta-hydroxy-5alpha-androstan-3-one
CC         {ECO:0000269|PubMed:10998348};
CC         KM=0.8 uM for 17beta-hydroxy-5alpha-androstan-3-one
CC         {ECO:0000269|PubMed:11158055};
CC         KM=1.44 uM for 5alpha-androstan-3,17-dione
CC         {ECO:0000269|PubMed:10998348};
CC         KM=5.04 uM for 3alpha-hydroxy-5alpha-androstan-17-
CC         one...(androsterone) {ECO:0000269|PubMed:10998348};
CC         Vmax=55.5 nmol/min/mg enzyme for 5alpha-androstane-3alpha,17beta-diol
CC         oxydation {ECO:0000269|PubMed:10998348};
CC         Vmax=51.9 nmol/min/mg enzyme for 17beta-hydroxy-5alpha-androstan-3-
CC         one reduction {ECO:0000269|PubMed:10998348};
CC         Vmax=55.5 nmol/min/mg enzyme for 5alpha-androstane-3alpha,17beta-diol
CC         oxidation {ECO:0000269|PubMed:10998348};
CC         Vmax=48.4 nmol/min/mg enzyme for 5alpha-androstan-3,17-dione
CC         reduction {ECO:0000269|PubMed:10998348};
CC         Vmax=55.5 nmol/min/mg enzyme for 3alpha-hydroxy-5alpha-androstan-17-
CC         one oxydation {ECO:0000269|PubMed:10998348};
CC         Note=kcat is 1.99 min(-1) for 17beta-hydroxy-5alpha-androstan-3-one
CC         reduction. kcat is 1.79 min(-1) for 5alpha-androstan-3,17-dione
CC         reduction. kcat is 2.1 min(-1) for 5alpha-androstane-3alpha,17beta-
CC         diol oxydation. kcat is 1.39.1 min(-1) for 3alpha-hydroxy-5alpha-
CC         androstan-17-one oxydation (PubMed:10998348). kcat is 2.1 min(-1) for
CC         5alpha-androstane-3alpha,17beta-diol oxydation (PubMed:10998348).
CC         kcat is 3.07 min(-1) for 5alpha-dihydrotestosterone sulfate
CC         (PubMed:19218247). kcat is 3.28 min(-1) for 5alpha-
CC         dihydrotestosterone 17-O-(beta-D-glucuronate) (PubMed:19218247).
CC         {ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:19218247};
CC   -!- PATHWAY: Steroid metabolism. {ECO:0000269|PubMed:14672942}.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|Ref.18}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:Q04828}.
CC   -!- TISSUE SPECIFICITY: Liver specific. {ECO:0000269|PubMed:10998348,
CC       ECO:0000269|PubMed:11158055, ECO:0000269|PubMed:7650035}.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- POLYMORPHISM: The allele with Cys-145/Val-311 shows a three- to five-
CC       fold decrease in catalytic efficiency for xenobiotic and steroidal
CC       substrates compared to the Ser-145/Leu-311 allele.
CC       {ECO:0000269|PubMed:10634139}.
CC   -!- DISEASE: 46,XY sex reversal 8 (SRXY8) [MIM:614279]: A disorder of sex
CC       development. Affected individuals have a 46,XY karyotype but present as
CC       phenotypically normal females. {ECO:0000269|PubMed:21802064}. Note=The
CC       gene represented in this entry may act as a disease modifier. A
CC       splicing mutation resulting in loss of AKR1C4 exon 2 has been found in
CC       affected individuals carrying a causative mutation in AKR1C2
CC       (PubMed:21802064). These patients manifest a more severe disease
CC       phenotype than individuals only carrying mutations in AKR1C2.
CC       {ECO:0000269|PubMed:21802064}.
CC   -!- SIMILARITY: Belongs to the aldo/keto reductase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35658.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S68287; AAD14010.1; -; mRNA.
DR   EMBL; AB045829; BAA99542.1; -; mRNA.
DR   EMBL; AB031085; BAA92885.1; -; mRNA.
DR   EMBL; AB032163; BAA92893.1; -; Genomic_DNA.
DR   EMBL; AL355303; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC020744; AAH20744.1; -; mRNA.
DR   EMBL; M33375; AAA35658.1; ALT_INIT; mRNA.
DR   EMBL; D26125; BAA05122.1; -; mRNA.
DR   CCDS; CCDS7064.1; -.
DR   PIR; A57407; A57407.
DR   PIR; S59620; S59620.
DR   RefSeq; NP_001809.3; NM_001818.3.
DR   PDB; 2FVL; X-ray; 2.40 A; A/B/C=1-323.
DR   PDBsum; 2FVL; -.
DR   SMR; P17516; -.
DR   BioGRID; 107534; 5.
DR   IntAct; P17516; 3.
DR   STRING; 9606.ENSP00000369814; -.
DR   BindingDB; P17516; -.
DR   ChEMBL; CHEMBL4999; -.
DR   DrugBank; DB13751; Glycyrrhizic acid.
DR   DrugBank; DB06077; Lumateperone.
DR   DrugBank; DB00959; Methylprednisolone.
DR   DrugBank; DB00461; Nabumetone.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00717; Norethisterone.
DR   DrugBank; DB00776; Oxcarbazepine.
DR   DrugCentral; P17516; -.
DR   SwissLipids; SLP:000000805; -.
DR   iPTMnet; P17516; -.
DR   PhosphoSitePlus; P17516; -.
DR   SwissPalm; P17516; -.
DR   BioMuta; AKR1C4; -.
DR   DMDM; 308153631; -.
DR   jPOST; P17516; -.
DR   MassIVE; P17516; -.
DR   MaxQB; P17516; -.
DR   PaxDb; P17516; -.
DR   PeptideAtlas; P17516; -.
DR   PRIDE; P17516; -.
DR   ProteomicsDB; 53480; -.
DR   Antibodypedia; 24066; 290 antibodies.
DR   DNASU; 1109; -.
DR   Ensembl; ENST00000263126; ENSP00000263126; ENSG00000198610.
DR   Ensembl; ENST00000380448; ENSP00000369814; ENSG00000198610.
DR   GeneID; 1109; -.
DR   KEGG; hsa:1109; -.
DR   UCSC; uc001ihw.2; human.
DR   CTD; 1109; -.
DR   DisGeNET; 1109; -.
DR   GeneCards; AKR1C4; -.
DR   HGNC; HGNC:387; AKR1C4.
DR   HPA; ENSG00000198610; Tissue enriched (liver).
DR   MalaCards; AKR1C4; -.
DR   MIM; 600451; gene.
DR   MIM; 614279; phenotype.
DR   neXtProt; NX_P17516; -.
DR   OpenTargets; ENSG00000198610; -.
DR   Orphanet; 443087; 46,XY disorder of sex development due to testicular 17,20-desmolase deficiency.
DR   PharmGKB; PA24680; -.
DR   VEuPathDB; HostDB:ENSG00000198610.10; -.
DR   eggNOG; KOG1577; Eukaryota.
DR   GeneTree; ENSGT00940000163771; -.
DR   HOGENOM; CLU_023205_0_0_1; -.
DR   InParanoid; P17516; -.
DR   OMA; KLWPTDQ; -.
DR   OrthoDB; 1016440at2759; -.
DR   PhylomeDB; P17516; -.
DR   TreeFam; TF106492; -.
DR   BioCyc; MetaCyc:HS10739-MONOMER; -.
DR   BRENDA; 1.1.1.357; 2681.
DR   PathwayCommons; P17516; -.
DR   Reactome; R-HSA-193368; Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol.
DR   Reactome; R-HSA-193775; Synthesis of bile acids and bile salts via 24-hydroxycholesterol.
DR   Reactome; R-HSA-193807; Synthesis of bile acids and bile salts via 27-hydroxycholesterol.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   SABIO-RK; P17516; -.
DR   SIGNOR; P17516; -.
DR   BioGRID-ORCS; 1109; 5 hits in 949 CRISPR screens.
DR   ChiTaRS; AKR1C4; human.
DR   EvolutionaryTrace; P17516; -.
DR   GeneWiki; 3-alpha-HSD; -.
DR   GenomeRNAi; 1109; -.
DR   Pharos; P17516; Tbio.
DR   PRO; PR:P17516; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P17516; protein.
DR   Bgee; ENSG00000198610; Expressed in right lobe of liver and 64 other tissues.
DR   Genevisible; P17516; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0044594; F:17-beta-hydroxysteroid dehydrogenase (NAD+) activity; IEA:RHEA.
DR   GO; GO:0072582; F:17-beta-hydroxysteroid dehydrogenase (NADP+) activity; IEA:RHEA.
DR   GO; GO:0047024; F:5alpha-androstane-3beta,17beta-diol dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004032; F:alditol:NADP+ 1-oxidoreductase activity; IBA:GO_Central.
DR   GO; GO:0004033; F:aldo-keto reductase (NADP) activity; TAS:ProtInc.
DR   GO; GO:0047044; F:androstan-3-alpha,17-beta-diol dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047023; F:androsterone dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0032052; F:bile acid binding; IBA:GO_Central.
DR   GO; GO:0015125; F:bile acid transmembrane transporter activity; TAS:ProtInc.
DR   GO; GO:0047743; F:chlordecone reductase activity; IDA:UniProtKB.
DR   GO; GO:0047834; F:D-threo-aldose 1-dehydrogenase activity; IEA:InterPro.
DR   GO; GO:0035410; F:dihydrotestosterone 17-beta-dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0009055; F:electron transfer activity; TAS:UniProtKB.
DR   GO; GO:0047086; F:ketosteroid monooxygenase activity; IBA:GO_Central.
DR   GO; GO:0016655; F:oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor; IDA:UniProtKB.
DR   GO; GO:0001758; F:retinal dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0016229; F:steroid dehydrogenase activity; IBA:GO_Central.
DR   GO; GO:0047045; F:testosterone 17-beta-dehydrogenase (NADP+) activity; IEA:RHEA.
DR   GO; GO:0047035; F:testosterone dehydrogenase (NAD+) activity; IEA:RHEA.
DR   GO; GO:0008209; P:androgen metabolic process; TAS:ProtInc.
DR   GO; GO:0015721; P:bile acid and bile salt transport; TAS:ProtInc.
DR   GO; GO:0006699; P:bile acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0071395; P:cellular response to jasmonic acid stimulus; IDA:UniProtKB.
DR   GO; GO:0044597; P:daunorubicin metabolic process; IMP:UniProtKB.
DR   GO; GO:0044598; P:doxorubicin metabolic process; IMP:UniProtKB.
DR   GO; GO:0042448; P:progesterone metabolic process; IBA:GO_Central.
DR   GO; GO:0006693; P:prostaglandin metabolic process; IBA:GO_Central.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0008202; P:steroid metabolic process; IBA:GO_Central.
DR   CDD; cd19108; AKR_AKR1C1-35; 1.
DR   Gene3D; 3.20.20.100; -; 1.
DR   InterPro; IPR020471; AKR.
DR   InterPro; IPR044482; AKR1C.
DR   InterPro; IPR018170; Aldo/ket_reductase_CS.
DR   InterPro; IPR023210; NADP_OxRdtase_dom.
DR   InterPro; IPR036812; NADP_OxRdtase_dom_sf.
DR   Pfam; PF00248; Aldo_ket_red; 1.
DR   PIRSF; PIRSF000097; AKR; 1.
DR   PRINTS; PR00069; ALDKETRDTASE.
DR   SUPFAM; SSF51430; SSF51430; 1.
DR   PROSITE; PS00798; ALDOKETO_REDUCTASE_1; 1.
DR   PROSITE; PS00062; ALDOKETO_REDUCTASE_2; 1.
DR   PROSITE; PS00063; ALDOKETO_REDUCTASE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cytoplasm; Direct protein sequencing; NADP; Oxidoreductase;
KW   Reference proteome.
FT   CHAIN           1..323
FT                   /note="Aldo-keto reductase family 1 member C4"
FT                   /id="PRO_0000124640"
FT   NP_BIND         20..24
FT                   /note="NADP"
FT                   /evidence="ECO:0000269|Ref.18"
FT   NP_BIND         166..167
FT                   /note="NADP"
FT                   /evidence="ECO:0000269|Ref.18"
FT   NP_BIND         216..221
FT                   /note="NADP"
FT                   /evidence="ECO:0000269|Ref.18"
FT   NP_BIND         270..280
FT                   /note="NADP"
FT                   /evidence="ECO:0000269|Ref.18"
FT   ACT_SITE        55
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000250"
FT   BINDING         50
FT                   /note="NADP"
FT                   /evidence="ECO:0000269|Ref.18"
FT   BINDING         117
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         190
FT                   /note="NADP"
FT                   /evidence="ECO:0000269|Ref.18"
FT   SITE            54
FT                   /note="Important for substrate specificity"
FT                   /evidence="ECO:0000250"
FT   SITE            84
FT                   /note="Lowers pKa of active site Tyr"
FT                   /evidence="ECO:0000250|UniProtKB:P14550"
FT   VARIANT         135
FT                   /note="G -> E (in dbSNP:rs11253043)"
FT                   /id="VAR_028240"
FT   VARIANT         145
FT                   /note="S -> C (in dbSNP:rs3829125)"
FT                   /evidence="ECO:0000269|PubMed:10634139"
FT                   /id="VAR_013290"
FT   VARIANT         170
FT                   /note="C -> Y (in dbSNP:rs17851824)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_028241"
FT   VARIANT         250
FT                   /note="Q -> R (in dbSNP:rs4880718)"
FT                   /evidence="ECO:0000269|PubMed:10634139,
FT                   ECO:0000269|PubMed:10672042, ECO:0000269|PubMed:11158055,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:2187532,
FT                   ECO:0000269|PubMed:7626489, ECO:0000269|PubMed:7650035,
FT                   ECO:0000269|PubMed:8172617, ECO:0000269|PubMed:8274401"
FT                   /id="VAR_028242"
FT   VARIANT         311
FT                   /note="L -> V (in dbSNP:rs17134592)"
FT                   /evidence="ECO:0000269|PubMed:10634139"
FT                   /id="VAR_013291"
FT   HELIX           3..5
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   STRAND          7..9
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   STRAND          15..22
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           33..44
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   STRAND          48..50
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           53..55
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           58..71
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           76..78
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   STRAND          80..85
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           87..89
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           92..106
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   STRAND          111..117
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   STRAND          124..126
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           144..156
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   STRAND          159..167
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           170..177
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   STRAND          187..192
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           200..208
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   STRAND          212..217
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   TURN            225..227
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           235..237
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           239..247
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           252..262
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   STRAND          266..270
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           274..280
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           281..285
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           290..297
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   HELIX           309..311
FT                   /evidence="ECO:0007744|PDB:2FVL"
FT   STRAND          318..321
FT                   /evidence="ECO:0007744|PDB:2FVL"
SQ   SEQUENCE   323 AA;  37067 MW;  E728CE4B420E8C58 CRC64;
     MDPKYQRVEL NDGHFMPVLG FGTYAPPEVP RNRAVEVTKL AIEAGFRHID SAYLYNNEEQ
     VGLAIRSKIA DGSVKREDIF YTSKLWCTFF QPQMVQPALE SSLKKLQLDY VDLYLLHFPM
     ALKPGETPLP KDENGKVIFD TVDLSATWEV MEKCKDAGLA KSIGVSNFNC RQLEMILNKP
     GLKYKPVCNQ VECHPYLNQS KLLDFCKSKD IVLVAHSALG TQRHKLWVDP NSPVLLEDPV
     LCALAKKHKQ TPALIALRYQ LQRGVVVLAK SYNEQRIREN IQVFEFQLTS EDMKVLDGLN
     RNYRYVVMDF LMDHPDYPFS DEY
//
